This study is testing a combination of two oral medications, emavusertib and zanubrutinib, for people with chronic lymphocytic leukemia (CLL) and other B-cell malignancies (cancers that start in immune cells called B cells). The main goal is to see how well this combination works against the cancer. For some participants, success will be measured by whether the cancer cells become undetectable (undetectable measurable residual disease or uMRD). For others, success will be measured by the overall response rate (how many people have their cancer shrink or disappear). You may be able to join if you are 18 or older, have a confirmed diagnosis of CLL, and meet other health criteria. The study plans to enroll 108 participants, but its current recruitment status is unclear.

Study design

This is an interventional study, meaning participants will receive a specific treatment. It plans to enroll 108 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for anticancer activity for up to approximately 23 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.